Substantial portion of cancer patients in early trials access drugs that are later approved, study finds

Substantial portion of cancer patients in early trials access drugs that are later approved, study finds

A paper in the Journal of the National Cancer Institute finds that almost 20% of patients in middle-stage cancer drug trials receive treatment that eventually proves effective enough to get FDA approval. This may have important implications for drug development and clinical trial recruitment.

One in Six Phase II Trial Participants Receive Cancer Drugs that Advance to Approval

Research carried out at McGill University has shown that one in six patients with cancer who participate in Phase II clinical trials receive a treatment that is eventually approved by the FDA. The findings could help patients and clinicians manage expectations when patients enroll in Phase II trials. “Right now, patients are not really given much information about how likely it is they will benefit from participating in a trial,” explained senio…

Many Early-Stage Cancer Trial Patients Gain Access to Future Approved

A significant recent study published in the Journal of the National Cancer Institute has illuminated an essential aspect of drug development in oncology, particularly concerning phase 2 clinical trials for cancer therapies. This groundbreaking investigation, which surveyed data from over 2,700 trials, reveals that nearly 20% of patients participating in middle-stage cancer drug trials may receive treatments that gain FDA approval. Such findings …